Latest News

Carriers of two genetic mutations at greater risk for illness and death from COVID-19

Tel Aviv University researchers suggest that carriers of the genetic mutations PiZ and PiS are at high risk for severe illness and even death from COVID-19. These mutations lead to deficiency in the alpha1-antitrypsin protein, which protects lung tis
Read More

Healthy PiMZ Alphas required for a new trial

If you are a healthy PiMZ then please consider taking part in this exciting Alpha-1 clinical trial. Please contact HMR direct using the contact email shown below quoting 20B005 in your email. If you have any concerns with participating right now due
Read More

First subject dosed with ZF874, a potential disease-modifying treatment for alpha-1-antitrypsin deficiency

Z Factor Ltd, a Cambridge-based drug development company spun out of the University of Cambridge, announced that the first human volunteer was dosed today with ZF874, its novel treatment for alpha-1-antitrypsin deficiency (AATD). AATD is a common gen
Read More

RCSI team to start trial for promising Covid-19 therapy for severe infections

Researchers in Ireland are hoping to add to the growing list of drug candidates for the treatment of patients with severe Covid-19 infection. A team from the Royal College of Surgeons in Ireland (RCSI) has published a paper in the American Journal of
Read More

New Board members to our charity

Alpha-1 Awareness is a charity founded and run by volunteers to help bring awareness of AATD as well as give support to those affected, their families, friends and carers.  We can’t do this alone, and we are so thankful to those who help in our Faceb
Read More

AlphaNet Announces New Appointment to the Board of Directors

AlphaNet is pleased to announce the appointment of Dell Witcher to the board of directors, effective May 14, 2020. “Dell’s expertise and involvement in our board will greatly benefit the Alpha-1 community.” “We are excited to welcome Dell to AlphaNet
Read More